Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cinryze for acute antibody-mediated rejection after kidney transplant
NL-OMON44758Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Mar 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Antibody-mediated kidney allograft rejection (AMR) comparing Cinryze + standard treatment with Placebo + standard treatment (2 arms). Primary endpoint: Primary efficacy endpoint. Started Mar 2017; status: recruiting.
02
Drugs
c1-esterase inhibitor
03
Conditions
Antibody-mediated kidney allograft rejection (AMR)
Beyond the preview
Go deeper on NL-OMON44758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44758.